Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variants
Phase of Trial: Phase IV
Latest Information Update: 21 Mar 2017
At a glance
- Drugs Daclatasvir (Primary) ; Dasabuvir; Ledipasvir/sofosbuvir; Ombitasvir/paritaprevir/ritonavir; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Adverse reactions
- 15 Mar 2017 Planned number of patients changed from 11 to 111.
- 01 Dec 2016 Planned number of patients changed from 222 to 11.
- 01 Dec 2016 Planned End Date changed from 9 Jun 2017 to 9 Feb 2018.